Compare Stocks: PYXS, ALMS, SVRA, and CRVS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.77 -0.6%	$21.56	$3.76 ▼ $31.35	$1.01B	-0.81	4.39 million shs	6.38 million shs
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
PYXS Pyxis Oncology	$3.33 -2.3%	$3.10	$1.03 ▼ $5.55	$277.75M	1.34	895,960 shs	563,433 shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.10B	0.25	1.34 million shs	2.18 million shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	0.00%	-15.36%	-66.01%	-66.81%	+88.14%
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-12.35%	+5.46%	+116.93%
PYXS Pyxis Oncology	0.00%	+3.74%	+6.73%	+64.04%	+50.68%
SVRA Savara	0.00%	+1.32%	-2.19%	-2.36%	+49.17%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALMS Alumis	$7.77 -0.6%	$21.56	$3.76 ▼ $31.35	$1.01B	-0.81	4.39 million shs	6.38 million shs
CRVS Corvus Pharmaceuticals	$12.56 +0.1%	$14.00	$5.74 ▼ $26.95	$1.06B	0.87	823,602 shs	4.46 million shs
PYXS Pyxis Oncology	$3.33 -2.3%	$3.10	$1.03 ▼ $5.55	$277.75M	1.34	895,960 shs	563,433 shs
SVRA Savara	$5.37 -0.9%	$5.49	$3.34 ▼ $7.01	$1.10B	0.25	1.34 million shs	2.18 million shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALMS Alumis	0.00%	-15.36%	-66.01%	-66.81%	+88.14%
CRVS Corvus Pharmaceuticals	0.00%	-2.71%	-12.35%	+5.46%	+116.93%
PYXS Pyxis Oncology	0.00%	+3.74%	+6.73%	+64.04%	+50.68%
SVRA Savara	0.00%	+1.32%	-2.19%	-2.36%	+49.17%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALMS Alumis	2.85	Moderate Buy	$33.27	328.22% Upside
CRVS Corvus Pharmaceuticals	2.88	Moderate Buy	$33.33	165.39% Upside
PYXS Pyxis Oncology	2.70	Moderate Buy	$8.75	162.76% Upside
SVRA Savara	2.88	Moderate Buy	$10.00	86.22% Upside

Current Analyst Ratings Breakdown

Latest PYXS, ALMS, SVRA, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/16/2026	ALMS Alumis	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/16/2026	CRVS Corvus Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/10/2026	PYXS Pyxis Oncology	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$6.00 ➝ $8.00
9/10/2026	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$7.00 ➝ $8.00
9/9/2026	PYXS Pyxis Oncology	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$12.00 ➝ $19.00
9/3/2026	ALMS Alumis	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
9/2/2026	ALMS Alumis	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$55.00 ➝ $37.00
9/2/2026	ALMS Alumis	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$39.00 ➝ $29.00
9/2/2026	ALMS Alumis	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $25.00
9/2/2026	ALMS Alumis	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00 ➝ $15.00
9/1/2026	ALMS Alumis	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$27.00

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALMS Alumis	$24.05M	41.82	N/A	N/A	$2.88 per share	2.70
CRVS Corvus Pharmaceuticals	N/A	N/A	$0.13 per share	99.08	$0.73 per share	N/A
PYXS Pyxis Oncology	$13.86M	20.04	N/A	N/A	$0.86 per share	3.87
SVRA Savara	N/A	N/A	N/A	N/A	$1.00 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALMS Alumis	-$243.32M	-$3.86	N/A	N/A	N/A	-5,933.46%	-93.15%	-74.50%	11/12/2026 (Estimated)
CRVS Corvus Pharmaceuticals	-$15.28M	-$0.61	N/A	N/A	N/A	N/A	-36.15%	-33.62%	11/3/2026 (Estimated)
PYXS Pyxis Oncology	-$79.62M	-$1.41	N/A	N/A	N/A	N/A	-215.23%	-112.19%	11/2/2026 (Estimated)
SVRA Savara	-$118.84M	-$0.58	N/A	N/A	N/A	N/A	-90.28%	-68.95%	11/11/2026 (Estimated)

Latest PYXS, ALMS, SVRA, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ALMS Alumis	-$0.7670	-$1.11	-$0.3430	-$1.11	$3.65 million	$1.66 million
8/13/2026	Q2 2026	PYXS Pyxis Oncology	-$0.35	-$0.40	-$0.05	-$0.40	$0.03 million	N/A
8/11/2026	Q2 2026	SVRA Savara	-$0.1413	-$0.16	-$0.0188	-$0.16	$2.00 million	N/A
8/6/2026	Q2 2026	CRVS Corvus Pharmaceuticals	-$0.1591	-$0.19	-$0.0309	-$0.19	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALMS Alumis	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
SVRA Savara	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALMS Alumis	N/A	6.74	6.74
CRVS Corvus Pharmaceuticals	N/A	16.16	16.16
PYXS Pyxis Oncology	N/A	1.34	1.34
SVRA Savara	0.21	10.13	10.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALMS Alumis	N/A
CRVS Corvus Pharmaceuticals	46.64%
PYXS Pyxis Oncology	39.07%
SVRA Savara	87.93%

Insider Ownership

Company	Insider Ownership
ALMS Alumis	33.70%
CRVS Corvus Pharmaceuticals	19.70%
PYXS Pyxis Oncology	5.70%
SVRA Savara	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALMS Alumis	239	129.43 million	85.82 million	N/A
CRVS Corvus Pharmaceuticals	37	84.12 million	67.55 million	Optionable
PYXS Pyxis Oncology	56	83.41 million	78.65 million	Optionable
SVRA Savara	70	205.46 million	194.57 million	Optionable

PYXS, ALMS, SVRA, and CRVS Headlines

Recent News About These Companies

Savara Inc. (NASDAQ:SVRA) Given Consensus Rating of "Moderate Buy" by Analysts

September 18 at 4:13 AM | marketbeat.com

Bank of New York Mellon Corp Acquires New Shares in Savara Inc. $SVRA

September 8, 2026 | marketbeat.com

Jupiter Topco LLC Invests $2.88 Million in Savara Inc. $SVRA

September 3, 2026 | marketbeat.com

BlackRock Inc. Takes $76.97 Million Position in Savara Inc. $SVRA

August 31, 2026 | marketbeat.com

6,976,810 Shares in Savara Inc. $SVRA Purchased by Nantahala Capital Management LLC

August 29, 2026 | marketbeat.com

Algert Global LLC Purchases 464,645 Shares of Savara Inc. $SVRA

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Purchases New Shares in Savara Inc. $SVRA

August 26, 2026 | marketbeat.com

Spruce Street Capital LP Acquires New Shares in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Deutsche Bank AG Makes New $5.33 Million Investment in Savara Inc. $SVRA

August 25, 2026 | marketbeat.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis ...

August 24, 2026 | uk.finance.yahoo.com

Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026

August 24, 2026 | businesswire.com

Savara Inc. (NASDAQ:SVRA) Receives Average Rating of "Moderate Buy" from Analysts

August 24, 2026 | marketbeat.com

Savara Inc. (SVRA) Latest Press Releases & Corporate News - Yahoo Finance

August 20, 2026 | finance.yahoo.com

Savara Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026 | caledonianrecord.comC

Savara: High Potential Binary Bet Cruising To PDUFA After 3 Month Speed Bump

August 5, 2026 | seekingalpha.com

Savara (SVRA) Gets a Buy from Piper Sandler

July 24, 2026 | theglobeandmail.com

Here's Why You Should Add Savara Stock to Your Portfolio Now

July 22, 2026 | zacks.com

What Savara Investors Should Know About This 580,187-Option Exercise and FDA Timeline

June 27, 2026 | fool.com

What Is Driving Attention Toward Savara’s Rare Disease Strategy?

June 15, 2026 | kalkinemedia.comK

Savara Announces New Employment Inducement Grant

June 12, 2026 | businesswire.com

Savara Announces Chief Financial and Administrative Officer Transition

June 8, 2026 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, ALMS, SVRA, and CRVS Company Descriptions

Alumis NASDAQ:ALMS

$7.77 -0.05 (-0.64%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$7.87 +0.10 (+1.34%)

As of 09/18/2026 07:57 PM Eastern

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Corvus Pharmaceuticals NASDAQ:CRVS

$12.56 +0.01 (+0.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$12.50 -0.06 (-0.51%)

As of 09/18/2026 07:56 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Pyxis Oncology NASDAQ:PYXS

$3.33 -0.08 (-2.35%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$3.40 +0.07 (+2.16%)

As of 09/18/2026 07:56 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Savara NASDAQ:SVRA

$5.37 -0.05 (-0.92%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$5.44 +0.06 (+1.21%)

As of 09/18/2026 07:30 PM Eastern

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, ALMS, SVRA, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, ALMS, SVRA, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, ALMS, SVRA, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, ALMS, SVRA, and CRVS Company Descriptions

Alumis NASDAQ:ALMS

Corvus Pharmaceuticals NASDAQ:CRVS

Pyxis Oncology NASDAQ:PYXS

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PYXS, ALMS, SVRA, and CRVS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PYXS, ALMS, SVRA, and CRVS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PYXS, ALMS, SVRA, and CRVS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, ALMS, SVRA, and CRVS Company Descriptions

Alumis NASDAQ:ALMS

Corvus Pharmaceuticals NASDAQ:CRVS

Pyxis Oncology NASDAQ:PYXS

Savara NASDAQ:SVRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools